drugset
drugset / Trial / NCT02169466

Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide

NCT02169466 ↗

Phase 1 Completed 22 enrolled Bial - Portela C S.A.
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide 25 mg (Madopar HBS).

Timeline

Start
2009-01
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Madopar® HBS Unknown 25 mg —
Subject Madopar® HBS Unknown 100 mg —
Subject Opicapone Small molecule 25 mg Oral
Subject Opicapone Small molecule 50 mg Oral
Subject Opicapone Small molecule 100 mg Oral

Indications

Parkinson disease